

Shionogi to develop treatment for mycobacterial diseases

15 October 2019 | News

Enters into a new license agreement and research collaboration with Hsiri Therapeutics, Inc.



Japanese major research-driven pharmaceutical company Shionogi & Co., Ltd. has announced that it has entered into a new license agreement with US headquartered Hsiri Therapeutics, Inc. regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). This new collaboration will include technology that complements Shionogi's earlier collaboration arrangement with Hsiri.

The new technology to be licensed from Hsiri has a novel mechanism of action, will be complementary to Shionogi's current research with Hsiri, and is anticipated to be more effective than current therapies for mycobacterial infections. Shionogi's strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri's innovative therapeutics in this collaborative program.

Under the terms of this agreement, Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration. Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi.